Why BHVN rose on Oct 22
Up 25% on Oct 22, and still 18% over its Oct 21 close.
“Biohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027.”
Follow BHVN's trial news. Pro members can get an alert when Biohaven files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 25% on Oct 22, and still 18% over its Oct 21 close.
“Biohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027.”
| Holding it back | 42.7% more shares than a year ago |
| Latest filing | 8-K, Oct 29 |
FDA accepts Biohaven's resubmitted troriluzole NDA for SCA with Q1 2027 goal date
BHVN closed +25.0% that day on 10.8x normal volume.
Wed Nov 18: AACR-NCI-EORTC (ENA) International…Industry event · date confirmed.
Expected to report Mon Mar 1, after the close
About 1 quarter
An officer, George C. Clark, bought 17,000 shares on Nov 17, 2025.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
BHVN is #95 of 270 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 95 |
Share count against a year before: BHVN +43%, OLMA +18%, VIR +22%, LXRX +22%.
Expected to report Mon Mar 1, after the close (in 105 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.86 a share, from $1.64.
“The decrease of $39.3 million was primarily due to decreases in direct program spend and preclinical spend in 2026 as compared to the same period in the prior year.”
BHVN's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The decrease of $3.6 million was primarily due to decreased employee costs, including non-cash share-based compensation expense.”
From its results filing (SEC filing · Oct 29)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 29, 2026 | -6.3% | -6.5% | -15.7% |
| Aug 10, 2026 | -3.7% | -0.3% | -0.6% |
| May 4, 2026 | +0.1% | -4.2% | -10.4% |
RSI 47.8, MACD below signal, above both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
BHVN scores 2 today, which Breakaway calls Below Average. It is #95 of 270 in Biotech by Quality Score, with 3 of 14 chart checks firing. Up 25% on Oct 22, and still 18% over its Oct 21 close. Cash lasts about 1 quarter at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BHVN scores 2 today, which Breakaway calls Below Average (0 to 5). That is #95 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BHVN's 2.
Expected to report Mon Mar 1, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. BHVN closed higher after 0 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.